NEW YORK (GenomeWeb News) – Genetic Technologies today said that it has reached a settlement with Roche 454 Life Sciences over alleged infringement of Genetic Technologies' primary non-coding DNA patent.

The Australian firm said that it has reached a settlement, covenant, and license agreement with 454, which also covers its affiliates within Roche. The terms of the agreement are confidential.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.